Navigation Links
New Data Demonstrating the Impact of Opioid-Related Adverse Events on Total Hospital Cost Presented at American Society of Health-System Pharmacists Meeting
Date:12/5/2011

to urinary retention, pruritus and respiratory depression, some of which, such as respiratory depression, can be severe and life threatening," said Gary Oderda, PharmD, MPH, professor in the Department of Pharmacy Practice and director of the Utah Pharmacotherapy Outcomes Research Center at the University of Utah College of Pharmacy, who will present the poster. "In addition to the negative impact these events have on patients' recovery, these data indicate they place a significant economic burden on hospitals and health care systems, as well."

Dr. Oderda conducted this research in conjunction with TJ Gan, M.D., MHS, professor and vice chair, Department of Anesthesiology at Duke University Medical Center, and in collaboration with Premier Research Services, part of the Premier Healthcare Alliance. The research was supported by Pacira Pharmaceuticals, Inc.

"These data not only demonstrate the strong correlation between total opioid consumption, opioid-related adverse events and cost, but also highlight the value of a multimodal, opioid-sparing approach to postsurgical pain management," said Dr. Gan. "By utilizing a combination of therapeutics, surgeons can provide effective analgesia while limiting the adverse events associated with opioids, which could provide significant benefits to both patients and hospital economics."

A regional health system analysis conducted by Barnabas Health will also be presented at 2 p.m. CST today during a poster session at ASHP. The research was supported by Pacira Pharmaceuticals, Inc. This analysis identified patients undergoing total abdominal hysterectomy (TAH) in one of Barnabas Health's six hospitals from January 2007 to December 2010 in order to identify any relationship between opioid use and increased LOS and overall cost in patients undergoing TAH. 

The 97 TAH patients with the longest LOS, termed "outliers," were matched to a control group of TAH surgical patients in the database. Medical re
'/>"/>

SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
2. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
3. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
4. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
5. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
6. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
7. Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development
8. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
9. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
10. ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia
11. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Zafgen, Inc., a leading biopharmaceutical ... severely obese patients, today announced initial results from ... inhibitor of methionine aminopeptidase 2 (MetAP2), in patients ... genetic obesity.  These results showed improvements in body ...
(Date:1/14/2014)... 2014 InformEx, North America,s leading ... will hold the 30 th edition of its annual ... Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... fine chemical and specialty chemical companies will take part in ...
(Date:1/14/2014)... LEESBURG, Va. , Jan. 14, 2014 Animal Emergency Critical ... in Leesburg, Virginia is the first in ... hyperbaric oxygen chamber. Dr. Susan M. Barnes ... years. Dr. Barnes and husband, Dr. Cole Taylor , are ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... PRO-DEX, INC. (Nasdaq: PDEX ) invites investors and ... fiscal 2011 fourth quarter and full-year financial results. ... the internet on Wednesday, September 14, 2011 at 4:30 p.m. ... by visiting the Company,s website at www.pro-dex.com and ...
... (NASDAQ: PCYC ), a biopharmaceutical company focused ... the treatment of cancer and immune mediated diseases, today ... fourth fiscal quarter and fiscal year ended June 30, ... 12, 2011.  The company will conduct a conference call ...
Cached Medicine Technology:Pro-Dex, Inc. Announces Fiscal 2011 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast 2Pharmacyclics Announces Date of Fiscal Year End 2011 Financial Results and Conference Call 2
(Date:4/20/2014)... harmful effects in children, codeine continues to be prescribed ... UCSF Benioff Children,s Hospital San Francisco. , As reported ... include changing provider prescription behaviors to promote the use ... hydrocodone. , "Despite strong evidence against the use of ... to large numbers of them each year," said Sunitha ...
(Date:4/18/2014)... in The Gerontologist reports that ... with a decrease in anxiety about death and increases ... their lives. In particular, listening to gospel music is ... an increase in sense of control. , These associations ... and individuals of both low- and high-socioeconomic status. , ...
(Date:4/18/2014)... a brain-related discovery that could revolutionize doctors, perception ... opens up the possibility that environmental and/or genetic ... activity that the researchers have identified as helping ... Neuroscience has just published a paper about ... of psychology and his doctoral student John Gaspar, ...
(Date:4/17/2014)... chronic inflammation in non-cancerous prostate tissue may have nearly ... those with no inflammation, according to results of a ... Kimmel Cancer Center. , The link between persistent inflammation ... high-grade prostate cancer those with a Gleason score ... the most aggressive and rapidly growing prostate cancers. , ...
(Date:4/17/2014)... Experimental Biology and Medicine a multidisciplinary research ... Kenis in the Institute of Genomic Biology (IGB) ... Urbana-Champaign describe their recent work on subcellular redox ... cell functions including energy metabolism, signaling, and transcriptional ... normal cellular behavior, redox status has been recognized ...
Breaking Medicine News(10 mins):Health News:UCSF study finds codeine often prescribed to children, despite available alternatives 2Health News:Religious music brings benefit to seniors' mental health 2Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2
... , , , MANHATTAN, Kan., ... work of a K-State researcher are making headway in the effort ... Juergen Richt is a Regents Distinguished Professor at K-State,s College of ... work at K-State and with outside collaborators is revealing the characteristics ...
... Experts urge parents to get their kids, eyes checked regularly ... percent of kids aged 12 to 17 have trouble seeing ... the nearly 1,500 children in the survey, more than 25 ... though 45 percent of them wore some type of prescription ...
... , CHESTNUT HILL, Mass., Aug. 3 SkinCare ... live Artefill patient demonstration at the American Academy of Dermatology Summer ... collagen filler for the correction of smile lines and was one ... 31st. , , "Over the past several years ...
... , ALLEGAN, Mich., Aug. 3 Perrigo Company (Nasdaq: ... Pharmaceutical Industries Ltd. (Nasdaq: TEVA ) (previously Barr Laboratories ... Administration to market Triamcinolone Acetonide Nasal Spray containing a paragraph IV ... complete ANDA with a Paragraph IV certification for NASACORT AQ. The ...
... equipment alone is responsible for an increased number of ... to a study performed at San Luis Diagnostic Center ... that there was a significant increase in the number ... to digital mammography. The number of cancers detected prior ...
... in French . Heavy drinkers of ... cancer than the population at large, says a group of ... in the highest consumption category increased their risk of developing ... cancer by 50%. In all, the researchers found ...
Cached Medicine News:Health News:K-State Researcher, Collaborators Study Virulence of Pandemic H1N1 Virus; Work at K-State Would Protect Pig Industry If the Virus Jumps to Swine Populations 2Health News:Leading Boston Dermatologist Performs Live Artefill Patient Demonstration at American Academy of Dermatology Summer Meeting 2Health News:Perrigo Announces FDA Approval for Generic Version of NASACORT(R) AQ 2Health News:Perrigo Announces FDA Approval for Generic Version of NASACORT(R) AQ 3Health News:Heavy drinkers face significantly increased cancer risk 2
... Lomb PMMA Anterior Chamber Intraocular Lenses are ... in patients 60 years of age or ... removed by primary intracapsular cataract extraction; or ... a structural reason that the anterior chamber ...
... Amvisc Plus is the preferred viscoelastic ... viscoelastic that reliably works from the start ... unique, moderately cohesive profile of this viscoelastic ... vacuum forces associated with phacoemulsification remove only ...
... ENDOGEL is a sterile, non-pyrogenic solution ... is supplied in a disposable single ... fitting, delivering 0,85 ml. Sodium ... of repetitive chains of disaccharides, glucoronate, ...
... a sterile, non-pyrogenic, transparent viscoelastic preparation ... molecular weight (average molecular weight 4 ... 23 mg/mL of sodium hyaluronate 5000, ... N-acetylglucosamine and sodium glucuronate linked by ...
Medicine Products: